Submarine groundwater discharges (SGD), consisting of groundwater flow from both terrestrial and marine origins, is an important source of nutrients, contaminants, and other chemicals to the coastal waters, and has significant impacts and implications on coastal environment and ecology. This paper reviews the recent advances in quantifying the tide-induced SGD in various beach aquifers around the world by means of mathematical modeling, laboratory experiments, and field observations or their combinations. Numerous studies have shown that (1) the order of magnitude of SGD around the world estimated by radium isotope tracers typically ranges from 10² to 10³ m³ d⁻¹ m⁻¹ of the shoreline, (2) SGD is mainly of marine origin, i.e. the re-circulated seawater across the aquifer-sea interface, and (3) tide is one of the major forces driving seawater-groundwater circulation. The order of magnitude of the tidal contributions to SGD from beach aquifers reported in the literature is only 10 m³ d⁻¹ m⁻¹ length of shoreline, at least one order of magnitude smaller than the total SGD estimated by radium isotope tracers. This is obviously in contradiction with (3). The possible reasons for this contradiction may include (1) underestimation of the shoreline length due to neglecting many headlands, bays and banks of tidal rivers, and (2) negligence of the seawater-groundwater exchange from the seabed ranging from the nearshore areas to the continental shelf. Further research is needed to understand more about the contra-diction.

Background: In the era of combination therapy, there has been limited research on body composition. Specific body composition, such as sarcopenia, possesses the potential to serve as a predictive biomarker for toxic effects and clinical response in patients with urothelial carcinoma (UC) undergoing tislelizumab combined with gemcitabine and cisplatin (T + GC). Materials and Methods: A total of 112 UC patients who received T + GC were selected at the Affiliated Hospital of Xuzhou Medical University from April 2020 to January 2023. Baseline patient characteristics and detailed hematological parameters were collected using the electronic medical system and laboratory examinations. The computed tomography images of patients were analyzed to calculate psoas muscle mass index (PMI). We evaluated the association between sarcopenia (PMI < 4.5 cm²/m² in men; PMI < 3.3 cm²/m² in women) and both hematological toxicity and tumor response. Results: Overall, of the 112 patients (65.2% male, median age 56 years), 43 (38.4%) were defined as sarcopenia. Patients with sarcopenia were notably older (p = 0.037), more likely to have hypertension (p = 0.009), and had poorer ECOG-PS (p = 0.027). Patients with sarcopenia were more likely to develop leukopenia (OR 2.969, 95% CI 1.028–8.575, p = 0.044) after receiving at least two cycles of T + GC. However, these significant differences were not observed in thrombocytopenia and anemia. There were no significant differences in the tumor response and grade 3–4 hematological toxicity between patients with sarcopenia and those without sarcopenia. Conclusions: Patients with sarcopenia were more likely to develop leukopenia after receiving T + GC. There were no notable alterations observed in relation to anemia or thrombocytopenia. No significant difference was found between the sarcopenia group and non-sarcopenia group in terms of tumor response and grade 3–4 hematological toxicity.

Purpose: The objective of this study aimed to explore whether the original IVC regimen should be continued after the second TURBT or whether the IVC induction phase should be restarted from the beginning. Methods: A retrospective analysis was performed on 137 patients who underwent a second TURBT at the Affiliated Hospital of Xuzhou Medical University between April 2014 and June 2022. Based on the pathological findings, patients were divided into two groups: group A patients, who did not have a residual tumor on pathological examination after the second TURBT; and group B patients, who had residual tumor. Recurrence was determined using cystoscopy and imaging every three months. The endpoint was recurrence-free survival. Result: In the entire cohort, there was a statistically significant difference in the RFS between patients in the two IVC regimens (p = 0.029). The RFS of patients in group B1 was significantly lower than that of patients in group B2 (p = 0.009). There was no significant difference in RFS between the subgroups A1 and A2 (p = 0.560). Multivariate Cox regression analysis confirmed that the IVC regimen after a second TURBT (p = 0.012) and T stage after a second TURBT (p = 0.005) were both independent predictors for patient RFS. Conclusion: If the pathological findings of the second TURBT specimen is benign, patients can continue their previous treatment regimen without restarting an IVC induction phase. Unnecessary IVC can be avoided in these patients. In contrast, for patients with residual tumors in the second TURBT specimen, the need to restart the IVC induction phase should be emphasized to improve patient prognosis.